1-6 of 6
Alvin Wong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Tanya Dorff, Lisa G. Horvath, Karen Autio, Alice Bernard-Tessier, Matthew B. Rettig, Jean-Pascal Machiels, Mehmet A. Bilen, Martijn P. Lolkema, Nabil Adra, Sylvie Rottey, Richard Greil, Nobuaki Matsubara, Daniel S.W. Tan, Alvin Wong, Hiroji Uemura, Charlotte Lemech, Johannes Meran, Youfei Yu, Mukul Minocha, Mason McComb, Hweixian Leong Penny, Vinita Gupta, Xuguang Hu, Gabor Jurida, Hosein Kouros-Mehr, Margit M. Janát-Amsbury, Tobias Eggert, Ben Tran
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1488–1500.
https://doi.org/10.1158/1078-0432.CCR-23-2978
Published: 15 April 2024
View article titled, A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

Melissa Alsina, Suzanne Trudel, Richard R. Furman, Peter J. Rosen, Owen A. O'Connor, Raymond L. Comenzo, Alvin Wong, Lori A. Kunkel, Christopher J. Molineaux, Andre Goy
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4830–4840.
https://doi.org/10.1158/1078-0432.CCR-11-3007
Published: 30 August 2012
View article titled, A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
Open the PDF for A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies

Kyriakos P. Papadopoulos, Sanjay Goel, Murali Beeram, Alvin Wong, Kavita Desai, Missak Haigentz, María L. Milián, Sridhar Mani, Anthony Tolcher, Alshad S. Lalani, John Sarantopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7110–7115.
https://doi.org/10.1158/1078-0432.CCR-08-0483
Published: 03 November 2008
View article titled, A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies
Open the PDF for A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies in another window
Journal Articles

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

Mark R. Albertella, Paul M. Loadman, Philip H. Jones, Roger M. Phillips, Roy Rampling, Neil Burnet, Chris Alcock, Alan Anthoney, Egils Vjaters, Chris R. Dunk, Peter A. Harris, Alvin Wong, Alshad S. Lalani, Chris J. Twelves
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1096–1104.
https://doi.org/10.1158/1078-0432.CCR-07-4020
Published: 15 February 2008
View article titled, Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study
Open the PDF for Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study in another window
Includes: Supplementary data
Journal Articles

Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

Alshad S. Lalani, Susan E. Alters, Alvin Wong, Mark R. Albertella, Jeffrey L. Cleland, William David Henner
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2216–2225.
https://doi.org/10.1158/1078-0432.CCR-06-2427
Published: 02 April 2007
View article titled, Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer
Open the PDF for Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer in another window
Journal Articles

Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer

Tomasz M. Beer, Milind Javle, Gilbert N. Lam, W. David Henner, Alvin Wong, Donald L. Trump
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7794–7799.
https://doi.org/10.1158/1078-0432.CCR-05-0552
Published: 08 November 2005
View article titled, Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer
Open the PDF for Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer in another window